Studying kidney disease and heart failure in people with obesity
Compares how kidneys handle protein and salt in people with heart failure and obesity.
Plain-language title generated from the registry record
Registry title: The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
Key facts
- Where
- Jackson, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07052539, who can take part
Where in United States
- University of Mississippi Medical CenterJackson, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Mississippi Medical Center
- Trial code
- NCT07052539
- Record updated
- 4 July 2025
- Original description
This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.Read full original descriptionShow less
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.
Inclusion: Adults 18-75 years old; Normal kidney function; No heart failure; BMI 25-30kg/m2; Adults 18-75 years old; eGFR >= 60 mL/min/1.73m2; BMI > 35 kg/m2; Adults 18-75 years old; eGFR >= 60 mL/min/1.73m2; BMI > 35 kg/m2; Diagnosis of HFpEF (chart diagnosis, LVEF > 55% on echo, H2FPEF score 6-9 or HFA-PEFF score 5 or 6.
Exclusion: Current use of nicotine or recreational drugs, chronic drinker; Criteria for Cohort 2: Obese Participants without HFpEF; Current use of nicotine or recreational drugs, chronic drinker; Criteria for Cohort 3: HFpEF and Obese Participants; Current use of nicotine or recreational drugs, chronic drinker; Diagnosis of chronic illness; History of cutaneous or allergic reaction to iodine-based products of contrast dyes; Acute illness or hospitalization event within 3 months; Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism; Diagnosis of Heart Failure; Diagnosis of chronic illness; History of cutaneous or allergic reaction to iodine-based products of contrast dyes; Acute illness or hospitalization event within 3 months; Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism; History of RRT or kidney transplant; Acute illness/hospitalization in the past 3 months; History of cancer, chemo, or XRT; History of allergies to contrast; Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism; eGFR<60mL/min/1.73m2; Hemoglobin levels <7mg/dL; eGFR<60mL/min/1.73m2; Hemoglobin levels <7mg/dL; Hemoglobin < 7; Pregnancy or breast feeding; Unable to stop NSAIDs; Pregnancy or breast feeding; Unable to stop NSAIDs; NYHA class III/IV; Urinary retention screen +; Mobility issues; Pregnant/breastfeeding; Unable to stop NSAIDs.
Criteria for Cohort 1: Healthy Participants.